Dewpoint Therapeutics Strengthens Collaboration with Novo Nordisk to Accelerate Drug Discovery

BOSTON - Just over a year after the start of its collaboration, Dewpoint Therapeutics and Novo Nordisk have decided to expand their research and development partnership.

The new agreement utilizes Dewpoint's high-throughput screening platform combined with genome-wide CRISPR screens.

Key goals of the expanded partnership

Leverage Dewpoint's state-of-the-art platform and expertise in high content image-based phenotypic high throughput screening (HTS) with Novo Nordisk's Target Discovery Engine.

Create translatable tools and procedures that, in the future, will be applied to expedite drug discovery efforts.

This new collaboration is a testament to the shared commitment of both companies to advance drug discovery and improve patient outcomes.

Contact:

Email: [e-mail]

Michael Fenn

Email: [e-mail]

(C) 2024 Electronic News Publishing, source ENP Newswire